• Oxford Immunotec, of Oxford, UK, closed a $40 million financing round in preparation of its anticipated U.S. market launch of T-SPOT TB, a blood test for tuberculosis. The round was co-led by new investors Clarus Ventures and Wellington Partners, with Kuwait-based National Technology Enterprises Co. also joining as a new investor. Existing investors also participated, including the Prelude Trust, Quester and Dow Chemical Co. Oxford Immunotec, a diagnostics firm, develops its T-SPOT technology, which is a method for directly quantifying antigen-specific T cells. Its tuberculosis test already is sold in Europe, Canada and other countries worldwide.

• WellGen Inc., of North Brunswick, N.J., has completed its Series C financing totaling $9.5 million. The money will be used to advance its anti-obesity ingredient for functional foods, including the launch of a human study that already received institutional review board approval, and to conduct further studies of its recently patented product WG0401, an enriched extract from black tea which has demonstrated inflammation-fighting properties in multiple studies in humans. Investors include both new and existing WellGen shareholders. The financing was substantially oversubscribed, leading WellGen's board of directors to increase the size of the offering.